CN111019904A - 适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法 - Google Patents
适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法 Download PDFInfo
- Publication number
- CN111019904A CN111019904A CN201811179275.0A CN201811179275A CN111019904A CN 111019904 A CN111019904 A CN 111019904A CN 201811179275 A CN201811179275 A CN 201811179275A CN 111019904 A CN111019904 A CN 111019904A
- Authority
- CN
- China
- Prior art keywords
- sheep
- immortalized
- cells
- cell line
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001494479 Pecora Species 0.000 title claims abstract description 56
- 210000001550 testis Anatomy 0.000 title claims abstract description 41
- 238000010276 construction Methods 0.000 title claims description 10
- 208000002399 aphthous stomatitis Diseases 0.000 title description 3
- 230000005727 virus proliferation Effects 0.000 title description 2
- 241000700635 Orf virus Species 0.000 claims abstract description 35
- 101710128836 Large T antigen Proteins 0.000 claims abstract description 16
- 230000002381 testicular Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000713666 Lentivirus Species 0.000 claims abstract description 10
- 238000011161 development Methods 0.000 claims abstract description 5
- 229940031567 attenuated vaccine Drugs 0.000 claims abstract description 4
- 238000010370 cell cloning Methods 0.000 claims abstract description 4
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 4
- 238000012216 screening Methods 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 11
- 238000004806 packaging method and process Methods 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 8
- 210000000234 capsid Anatomy 0.000 claims description 7
- 239000013613 expression plasmid Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 244000309466 calf Species 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 241000283898 Ovis Species 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 229940055695 pancreatin Drugs 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- 210000003195 fascia Anatomy 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 8
- 230000010076 replication Effects 0.000 abstract description 6
- 230000003044 adaptive effect Effects 0.000 abstract description 4
- 230000029812 viral genome replication Effects 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002574 poison Substances 0.000 abstract description 3
- 231100000614 poison Toxicity 0.000 abstract description 3
- 238000012136 culture method Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 89
- 238000002360 preparation method Methods 0.000 description 5
- 239000012888 bovine serum Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019687 Lamb Nutrition 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000008034 Contagious Ecthyma Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010031071 Orf Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种适应羊口疮病毒(ORFV)增殖的永生化羊睾丸细胞系的构建方法,包括将SV40大T抗原通过慢病毒载体导入原代羊睾丸细胞,通过细胞克隆技术,筛选和纯化可持续传代的细胞,最终筛选出一株传代和生长性能良好的永生化细胞株。病毒感染和复制动力学试验表明,本发明所构建的永生化细胞系为ORFV适应细胞系,命名为羊睾丸细胞DST‑3,F10代细胞DST‑3接种ORFV AH‑GY13株,毒价达10‑6.4TCID50/ml,与在原代细胞中的复制水平相似。本发明为ORFV弱毒疫苗和灭活疫苗的研制与生产提供了稳定的细胞环境和标准化的培养方法。
Description
技术领域
本发明涉及永生化羊睾丸细胞系的构建方法,尤其涉及一种适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法,属于永生化羊睾丸细胞系的构建领域。
背景技术
羊传染性脓疱又称羊口疮,是一种由痘病毒科副痘病毒属的羊口疮病毒(ORFV)所致,主要侵害绵羊和山羊,使其黏膜和皮肤发生脓性溃疡的传染病。本病流行无明显季节性,但春秋季相对较易发生。常呈群发性流行,3~6月龄羔羊最易感染,病羊和带毒羊是本病的传染源。健康羊与病羊直接接触,或接触被病羊污染的用具、饮水、饲槽、饲料等而感染。病毒可随病羊的创口分泌物和唾液以及脱落的痴皮排出,主要经损伤的皮肤或黏膜而感染健康宿主。
ORFV需要在羊或牛的原代睾丸细胞中增殖。原代细胞制备工艺复杂,质量难以控制,并易污染外源病毒,有待改进。
目前,制备疫苗用细胞为羊或牛的原代睾丸细胞。该细胞生长缓慢,并随传代代次增加,细胞活力降低,细胞形态不好,最终失去传代能力。且羔羊睾丸来源有限,采集工作量大,并可能携带其他病原;细胞制作过程复杂耗时,易污染细菌,不利于批量生产使用。
永生化细胞是指体外培养的细胞自发的或在外界因素的影响下获得无限增殖能力的细胞。与肿瘤细胞不同的是,永生化细胞具有锚定依赖生长的特性和接触抑制的现象,这更类似有序的组织细胞。
提供一种适应ORFV增殖的永生化羊睾丸细胞系的构建方法对于ORFV弱毒疫苗和灭活疫苗的研制与生产具有重要意义。
发明内容
本发明的主要目的是提供一种适应ORFV增殖的永生化羊睾丸细胞系的构建方法;
本发明的主要目的是通过以下技术方案来实现的:
一种适应ORFV增殖的永生化羊睾丸细胞系的构建方法,包括:
(1)将SV40大T抗原基因克隆至慢病毒转移载体得到重组质粒;
(2)将重组质粒、包装载体和衣壳表达质粒转染至细胞进行病毒包装;将包装后的重组病毒导入原代羊睾丸细胞进行培养;
(3)通过单细胞克隆纯化筛选出适应ORFV增殖的永生化羊睾丸细胞系。
优选的,步骤(1)将SV40大T抗原基因克隆至慢病毒转移载体pSFG得到重组质粒pSFG-T;
优选的,步骤(2)所述的包装载体是Gag-pol包装载体;所述的衣壳表达质粒是VSV-G衣壳表达质粒;
优选的,步骤(3)中所述的羊睾丸原代细胞的制备方法包括:
(a)取新鲜采集的羔羊睾丸,用75%酒精清洗后再用灭菌PBS清洗,然后去除筋膜和结缔组织;
(b)将处理后的睾丸剪碎,再用灭菌PBS清洗后,加入0.25%胰酶消化;加入含10%新生牛血清的DMEM培养基终止消化;
(c)将羊睾丸细胞均匀分散开后过滤,将细胞分散计数,置于细胞培养瓶中在37℃CO2培养箱培养,获得羊睾丸原代细胞。
本发明将SV40大T抗原通过慢病毒载体导入原代羊睾丸细胞,使其永生化,并通过细胞克隆技术,筛选和纯化可持续传代的细胞,最终筛选出一株传代和生长性能良好的细胞株。病毒感染和复制动力学试验表明,所建立的细胞系为ORFV适应细胞系,该细胞系名称为羊睾丸细胞DST-3。本发明构建的永生化羊睾丸细胞系DST-3为ORFV适应细胞,F10代细胞DST-3接种ORFV AH-GY13株,毒价达10-6.4TCID50/ml,与在原代细胞中的复制水平相似。本发明的永生化细胞系的建立为ORFV弱毒疫苗和灭活疫苗的研制与生产提供了稳定的细胞环境和标准化的培养方法。
附图说明
图1SV40大T抗原基因PCR片段的琼脂糖凝胶电泳图。
图2羊睾丸原代细胞和永生化细胞(DST-3)对接种ORFV(AH-GY13株)后出现的细胞病变图。
具体实施方式
以下结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但这些实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
实施例1适应ORFV增殖的永生化羊睾丸细胞系的构建及鉴定
1试验材料
1.1细胞
SV40大T抗原基因来源HEK293T细胞购于中国科学院上海细胞所,plat E细胞由中国农业科学院哈尔滨兽医研究所惠赠,原代山羊睾丸细胞由安徽东方帝维生物制品公司制备。
1.2病毒
ORFV AH-GY13株,由安徽农业大学惠赠。
1.3引物
SV40大T抗原基因扩增引物
T1:5’-CTAGGATCCATGGATAAAGTTTTAAACAG AGA-3’
T2:5’-CTGGATCCTTATGTTTCAGGTTCAGGGGGAGG-3’
1.4细胞培养液
细胞生长液为含10%新生牛血清的DMEM。细胞接种ORFV后的维持液为含2%新生牛血清的DMEM。
2试验方法
2.1表达大T抗原的慢病毒制备
2.1.1大T抗原克隆
提取HEK293T细胞DNA,用上游引物Tl和下游引物T2经PCR扩增SV40大T抗原基因。
25μl反应体系为:Buffer 2.5μl、dNTP 2μl、引物Tl和T2各0.5μl、rTaq酶0.3μl、DNA模板1μl,去离子水补至25μl。
扩增程序为94℃3min;94℃50s、55℃50s、72℃60s,35个循环;72℃5min。
分别取扩增产物5μl,进行电泳分析及DNA测序,确认克隆的SV40大T抗原基因。对所扩增出的目的基因片段胶回收纯化,并在NcoI位点克隆至慢病毒转移载体pSFG,得到重组质粒pSFG-T。
2.1.2重组慢病毒包装和收获
取60mm培养皿,接种plat E 7×105细胞。当细胞聚合度达60%时,转染重组慢病毒所需质粒,包括18μg pSFG-T转移载体、12μg Gag-pol包装载体和6μg VSV-G衣壳表达质粒。37℃CO2培养箱培养48h,收集病毒液,10,000g离心5min,留上清,-80℃保存。
2.2原代细胞永生化
2.2.1羊睾丸原代细胞制备
取新鲜采集的1枚羔羊睾丸,用75%酒精清洗一遍,再用灭菌PBS清洗3次,然后去除筋膜和结缔组织,置于小烧杯内剪碎。灭菌PBS清洗3次后,转入盛放玻璃珠的三角瓶内,加入0.25%胰酶30ml,封口,置于37℃水浴中消化20min后,加入含10%新生牛血清的DMEM培养基终止消化。其后轻轻向一个方向摇动三角瓶,在玻璃珠的作用下,羊睾丸细胞均匀分散开,取放置16层纱布的漏斗过滤,将细胞分散计数,置于75cm2细胞培养瓶中,37℃CO2培养箱培养。由此获得羊睾丸原代细胞。
2.2.2羊睾丸细胞永生化
待原代细胞长至融合后传代,第二代细胞培养24h消化,取1×106细胞至15ml离心管内,加入重组慢病毒4.5ml,室温1,500g离心2h。弃上清后,用5ml含10%新生牛血清的DMEM重悬细胞,1×105细胞/孔加入六孔板中培养,每3天换液一次。大部分细胞凋亡脱落,少量细胞存活并长成岛状集落。
2.2.3永生化细胞分选
吸出有存活细胞集落细胞孔中的培养液,将浸泡0.25%胰酶后的直径5mm灭菌滤纸片覆盖集落细胞上,3min后取下,将附着的细胞移入24孔板(每孔0.5ml含10%新生牛血清的DMEM)。7天后选择细胞分裂较快的克隆,胰酶消化后转至6孔板继续培养,记为F1代。
2.2.4细胞传代特性检测
选择细胞增殖良好的克隆,扩大培养,并记录传代次数。从F4代选择5株保存,并保留一株(DST-3)继续传至F10代,并保存各代次细胞,同时检测对ORFV的易感性和支持病毒复制能力。
2.3病毒易感性和复制能力测定
2.3.1 ORFV制备
待原代羊睾丸细胞在75cm2培养瓶中长成单层,弃掉含10%新生牛血清的DMEM,PBS清洗3次,接种用无血清DMEM稀释为100TCID50的ORFV 3ml,置37℃5%CO2培养箱作用1h,弃去瓶内液体,然后加入2%新生牛血清DMEM维持液继续培养。待细胞病变达80%以上,收获病毒,-80℃保存备用。
2.3.2毒价测定
将原代羊睾丸细胞按1×105细胞/孔接种至96孔板,培养24h。将保存的ORFV以无血清DMEM做10倍系列稀释,取10-4-10-8稀释度接种细胞,100μl/孔培养48h。观察细胞病变孔数,记录结果,根据Reed-Muench氏法计算病毒TCID50。
3试验结果
3.1 SV40大T抗原基因扩增
293T细胞DNA为模板,以针对大T抗原基因的Tl/T2序列为引物,进行PCR扩增,得到与SV40大T抗原基因相符的大小约为2,154bp片段(图1)。
3.2原代羊睾丸细胞永生化
感染重组慢病毒的原代细胞在六孔板中持续培养后,多数细胞凋亡后脱落,但出现少量由细胞增殖后形成的集落。这些细胞集落(克隆)大多可以传代、增殖。通过筛选增殖快,细胞形态良好的克隆持续传代。经过10次传代最终选出1株永生化克隆,为羊睾丸细胞系DST-3。
3.3 ORFV在永生化羊睾丸细胞中的易感性和复制特性
用100TCID50的ORFV AH-GY13株分别接种原代和永生化羊睾丸细胞(DST-3),24h后,2种细胞均出现明显细胞病变(图2)。48h后收获细胞培养上清,检测病毒滴度(TCID50)。,3次实验结果显示,原代和永生化羊睾丸细胞的病毒复制水平相似,其毒价均在10- 6.4TCID50/ml左右(表1)。
表1.羊口疮病毒AH-GY13株在原代和永生化细胞中的复制水平
4试验结论
4.1本发明构建出羊睾丸细胞永生化细胞系,命名为DST-3。
4.2本发明构建的永生化羊睾丸细胞系为ORFV适应细胞,F10代细胞DST-3接种ORFV AH-GY13株,毒价达10-6.4TCID50/ml,与在原代细胞中的复制水平相似。
SEQUENCE LISTING
<110> 安徽东方帝维生物制品股份有限公司
<120> 适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法
<130> AH-3003-180913A
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 32
<212> DNA
<213> Artifical sequence
<400> 1
ctaggatcca tggataaagt tttaaacaga ga 32
<210> 2
<211> 32
<212> DNA
<213> Artifical sequence
<400> 2
ctggatcctt atgtttcagg ttcaggggga gg 32
Claims (10)
1.一种适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法,其特征在于,包括:
(1)将SV40大T抗原基因克隆至慢病毒转移载体得到重组质粒;
(2)将重组质粒、包装载体和衣壳表达质粒共转染细胞进行病毒包装;将包装后的重组病毒导入原代羊睾丸细胞进行培养;
(3)通过单细胞克隆纯化筛选出适应羊口疮病毒增殖的永生化羊睾丸细胞系。
2.按照权利要求1所述的构建方法,其特征在于,步骤(1)将SV40大T抗原基因克隆至慢病毒转移载体pSFG得到重组质粒pSFG-T。
3.按照权利要求1所述的构建方法,其特征在于,步骤(2)所述的包装载体是Gag-pol包装载体。
4.按照权利要求1所述的构建方法,其特征在于,步骤(2)所述的衣壳表达质粒是VSV-G衣壳表达质粒。
5.按照权利要求1所述的构建方法,其特征在于,步骤(3)中所述的羊睾丸原代细胞的制备方法包括:
(a)取新鲜采集的羊睾丸,用75%酒精清洗后再用灭菌PBS清洗,去除筋膜和结缔组织;
(b)将处理后的羊睾丸剪碎,用灭菌PBS清洗后,加入0.25%胰酶消化;加入含10%新生牛血清的DMEM培养基终止消化;
(c)将羊睾丸细胞均匀分散开后过滤,将细胞分散计数,培养,获得羊睾丸原代细胞。
6.按照权利要求5所述的构建方法,其特征在于,步骤(c)所述的培养是置于细胞培养瓶中在37℃CO2培养箱培养。
7.由权利要求1-6任何一项所述的构建方法得到的永生化羊睾丸细胞系。
8.按照权利要求7所述的永生化羊睾丸细胞系,其特征在于,其命名为羊睾丸细胞DST-3。
9.权利要求7所述的永生化羊睾丸细胞系在研制羊口疮病毒弱毒疫苗中的应用。
10.权利要求7所述的永生化羊睾丸细胞系在研制羊口疮病毒灭活疫苗中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811179275.0A CN111019904A (zh) | 2018-10-10 | 2018-10-10 | 适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811179275.0A CN111019904A (zh) | 2018-10-10 | 2018-10-10 | 适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111019904A true CN111019904A (zh) | 2020-04-17 |
Family
ID=70191904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811179275.0A Pending CN111019904A (zh) | 2018-10-10 | 2018-10-10 | 适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111019904A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113136361A (zh) * | 2021-06-11 | 2021-07-20 | 中国农业科学院兰州兽医研究所 | 一种羔绵羊睾丸支持细胞及其分离方法和应用 |
CN113355275A (zh) * | 2021-06-11 | 2021-09-07 | 中国农业科学院兰州兽医研究所 | 一种羔绵羊睾丸支持细胞、睾丸支持细胞亚克隆及其分离方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048710A (en) * | 1996-08-16 | 2000-04-11 | Genecor International, Inc. | Expression system for altered expression levels |
CN101016536A (zh) * | 2006-12-21 | 2007-08-15 | 福建医科大学 | 乙型肝炎病毒细胞株HepG2-RHBV的构建 |
CN101683533A (zh) * | 1995-02-28 | 2010-03-31 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
CN102533660A (zh) * | 2012-03-07 | 2012-07-04 | 西北农林科技大学 | 一种用于羊口疮病毒增殖的永久细胞系制备方法 |
-
2018
- 2018-10-10 CN CN201811179275.0A patent/CN111019904A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101683533A (zh) * | 1995-02-28 | 2010-03-31 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
US6048710A (en) * | 1996-08-16 | 2000-04-11 | Genecor International, Inc. | Expression system for altered expression levels |
CN101016536A (zh) * | 2006-12-21 | 2007-08-15 | 福建医科大学 | 乙型肝炎病毒细胞株HepG2-RHBV的构建 |
CN102533660A (zh) * | 2012-03-07 | 2012-07-04 | 西北农林科技大学 | 一种用于羊口疮病毒增殖的永久细胞系制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113136361A (zh) * | 2021-06-11 | 2021-07-20 | 中国农业科学院兰州兽医研究所 | 一种羔绵羊睾丸支持细胞及其分离方法和应用 |
CN113355275A (zh) * | 2021-06-11 | 2021-09-07 | 中国农业科学院兰州兽医研究所 | 一种羔绵羊睾丸支持细胞、睾丸支持细胞亚克隆及其分离方法和应用 |
CN113355275B (zh) * | 2021-06-11 | 2024-03-05 | 中国农业科学院兰州兽医研究所 | 一种羔绵羊睾丸支持细胞、睾丸支持细胞亚克隆及其分离方法和应用 |
CN113136361B (zh) * | 2021-06-11 | 2024-03-08 | 中国农业科学院兰州兽医研究所 | 一种羔绵羊睾丸支持细胞及其分离方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110218706B (zh) | 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用 | |
CN109837250B (zh) | 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用 | |
CN111019904A (zh) | 适应羊口疮病毒增殖的永生化羊睾丸细胞系的构建方法 | |
CN113528453A (zh) | 一种永生化猪巨噬细胞株及其构建方法和应用 | |
CN110368490B (zh) | 貉细小病毒性肠炎、犬瘟热二联灭活疫苗及其制备方法 | |
CN114381440A (zh) | 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用 | |
CN110452928A (zh) | 一株pk-15稳定细胞株的构建及应用 | |
CN116926022B (zh) | 一种鸽源基因Ⅵ型新城疫病毒mGZ08、用途、制备方法、培养方法、疫苗 | |
CN1654665A (zh) | 减毒痘苗病毒天坛株载体及制备方法和应用 | |
CN109536464B (zh) | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 | |
CN106191118B (zh) | 一种慢病毒干扰载体及其构建方法和应用 | |
CN104293736A (zh) | 一种端粒酶永生化牛甲状腺细胞系及其用途 | |
CN104762318B (zh) | 人凝血因子viii基因22号内含子倒位型突变的原位修复质粒、试剂盒及方法 | |
CN112852751A (zh) | 一种新冠肺炎核酸检测质控病毒的制备及质控方法 | |
CN109608535B (zh) | 一种优化的鸡α干扰素肽链及其重组表达工程菌株 | |
CN105420196A (zh) | 一种稳定表达hpv16 e5蛋白细胞株的构建方法及应用 | |
CN108060141B (zh) | Vp2基因和np基因重组腺病毒及其应用 | |
EP4222250A1 (en) | Bioreactor production of virus from adherent cells | |
Silva Jr et al. | Efficient assembly of full-length infectious clone of Brazilian IBDV isolate by homologous recombination in yeast | |
CN112870343A (zh) | 一种基于人造新冠病毒孵化细胞的灭活疫苗制备方法 | |
CN112342244B (zh) | 一种表达Furin蛋白的细胞株及其在禽传染性支气管炎病毒培养中的应用 | |
CN116445528B (zh) | 重组猪流行性腹泻病毒感染性克隆的构建方法及其感染性克隆和应用 | |
CN117568288B (zh) | 一种高效拯救禽冠状病毒的方法及其应用 | |
CN116479016B (zh) | 牛副流感病毒3型全长感染性克隆及其构建方法、用途 | |
CN118325853B (zh) | 表达h9n2亚型aiv ha基因的重组i型马立克病病毒株及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200417 |